SEHK:1672Biotechs
Ascletis Pharma (SEHK:1672) Is Up 9.9% After FDA Clears ASC30 Phase II Diabetes Trial - What's Changed
Ascletis Pharma announced that it received U.S. FDA Investigational New Drug clearance for a 13-week Phase II trial of its oral small-molecule GLP-1 candidate ASC30 in type 2 diabetes, with enrollment planned to start in the first quarter of 2026.
The clearance builds on prior Phase II obesity data in which ASC30 delivered dose-dependent weight loss and relatively favorable gastrointestinal tolerability, reinforcing its potential as an oral treatment option across major metabolic...